Pharsight

1. List of Apriso drug patents

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8865688	July, 2016	Terminated-Other
US8865688	July, 2016	Terminated-Other
US8865688	December, 2015	FWD Entered	SALIX PHARMACEUTICALS, LTD.	GeneriCo, LLC

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865688	VALEANT PHARMS INTL	Compositions and methods for treatment of bowel diseases with granulated mesalamine	May, 2030 (6 years from now)

Do you want to check out APRISO patents from before 2022?

Market Authorisation Date: 31 October, 2008

Treatment: For the maintenance of remission of ulcerative colitis

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.375 g	03 Apr, 2012	1		20 Apr, 2018	Extinguished

Strength	Dosage	Availability
375MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

United States

Canada

Mexico

China

Australia

South Africa

New Zealand

Israel

Ukraine

Japan

Chile

European Union

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8436051	ALLERGAN	Mesalamine suppository	Jun, 2028 (5 years from now)
US8217083	ALLERGAN	Mesalamine suppository	Jun, 2028 (5 years from now)

Do you want to check out CANASA patents from before 2022?

Market Authorisation Date: 05 January, 2001

Treatment: NA

Dosage: SUPPOSITORY;RECTAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1000 mg	24 May, 2013	1	24 Nov, 2015	06 Jun, 2028	Eligible

Strength	Dosage	Availability
1GM	SUPPOSITORY;RECTAL	Prescription
500MG	SUPPOSITORY;RECTAL	Discontinued